Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005)

Femme et Homme Max 99 ans
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005) MAJ Il y a 4 ans

A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Which Contained a Platinum Agent To evaluate the efficacy of YM155 based on objective tumor response rate (CR+PR) in patients with measurable disease based on RECIST criteria

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations